El interés en corto de My City Builders da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de My City Builders. Los datos de interés en corto se actualizan cada dos semanas.

My City Builders (OTC:MYCB) Bolsa, Informe de interés en corto

My City Builders Inc with its subsidiary focuses on real estate transactions, in which it buys and develops real estate for sale or rent of low-income housing. It also plans to invest in three sectors of the market by buying, refurbishing, and selling traditional foreclosures, buying, developing, and renting Land Banks that have an average pool of homes or lots, and buying, refurbishing, or developing and selling homes made available by the government through HECM pools.

MY CITY BUILDERS INC by My City Builders, Inc.

My City Builders Inc

RYVYL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) ("RYVYL" or the "Company"), a leading innovator of payment transaction solutions leveraging electronic payment technology, has submitted a registration statement on Form S-1 with the Securities and Exchange Commission. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Additionally, management is executing strategic actions and enhancing its business plan:
<ul>
<li>RYVYL is
<ul>
<li>Focusing on growing its North America revenues, including pursuing a legacy vertical market, which at its peak, in the fourth quarter of 2023, delivered revenue of $12 million;</li>
<li>Expanding its blockchain applications and crypto capabilities; and</li>
<li>Rightsizing the company as detailed below.</li>
</ul>
</li>
<li>The company has entered into a letter of intent (LOI) to acquire an entity with technology and digital assets that are complementary.</li>
<li>RYVYL has closed the sale of RYVYL EU, its wholly owned European subsidiary, and the transaction is complete. The company has withdrawn its previous guidance for 2025.</li>
</ul>
Cost Savings Initiatives and Organizational Realignment
In addition, on May 31, 2025, RYVYL realigned its corporate and North America operations and implemented a reduction in force of 18 employees, representing approximately 40% of its North America workforce. Savings from this action along with other reductions are expected to result in savings of approximately $780,000 per quarter. Plans to reduce outside engineering contractors during the second quarter of 2025 are expected to result in savings of approximately $265,000 per quarter. The Company expects the full impact of these savings to begin in the third quarter of 2025.
Additional Terms
The offering is expected to commence after the SEC completes its review process, subject to market and other conditions. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
There are no assurances that the Company will close the acquisition or that the Enhanced Business Plan would result in a significant benefit to the Company. In addition, the Acquisition and Enhanced Business Plan would be dependent upon the Company raising a minimum of $100 million, which would require shareholder approval of (i) the Acquisition, (ii) a potential increase in the authorized amount of common stock of the Company, and (iii) a potential reverse split of the common stock of the Company.

News

IPOs

RVYL

RYVYL Files for Stock Offering, Plans Cost Cuts and Crypto Expansion to Refocus US Business

Fury Gold Mines Limited (NYSE:<a href="https://www.benzinga.com/stock/FURY#NYSE">FURY</a>) ("Fury" or the "Company") is pleased to announce that is has finalized a number of drill targets at the Sakami gold project located in the Eeyou Istchee Territory in the James Bay region of Northern Quebec (Figure 1). The first phase drilling campaign will commence in late June 2025 and will be comprised of approximately 3,000 – 5,000 metres (m), with three priorities;
<ol>
<li>Discovery along a 23-kilometre (km) long gold-bearing structural corridor at the Juliette target;</li>
<li>Confirm historical mineralized intercepts at the La Pointe and La Pointe Extension targets;</li>
<li>Stepout drilling along strike and down plunge of a high-grade corridor identified at La Pointe Extension.</li>
</ol>

FURY

Fury Gold Mines Finalizes Number Of Drill Targets At Sakami Gold Project Located In Eeyou Istchee Territory In James Bay Region Of Northern Quebec

AMWD

American Woodmark CFO Paul Joachimczyk Resigns, CEO Scott Culbreth Named Interim Financial Officer

<a href="https://www.globenewswire.com/Tracker?data=rv7o-H8l-jTHoqhdWSfawILWPvFTQwhluDyjODnmujzbKOlDii3m1SfQwRofUtfEQIuvCNgbSbw9HdyRZfS4gA==">USA Rare Earth</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) (USAR or the Company) today announced it has signed a memorandum of understanding (MOU) with <a href="https://www.globenewswire.com/Tracker?data=BJyFqA3nAW4K9A56mCaK375RJQBr0MTWob_6mw-Dq2Q-GpnyRKzLGRYBdWxs0jE67QBXgZuFMgjslooskSXT5pQ1mbbNj7NjpL-sQzOLVAE=">Moog Electric Motion Solutions</a> (Moog) for delivery of the Company's neo magnets, of which USAR plans to begin production in early 2026. Moog Electric Motion Solutions provides precision motion and fluid control systems and will begin prototyping USAR's neo magnets for use in Moog's high-performance coolant distribution pumps used in data centers around the world.
The MOU is the latest in a series of agreements with potential customers announced by the Company following the March 31, 2025, commissioning of its Innovations Lab in Stillwater, Oklahoma. USAR's Innovations Lab mimics the production capabilities of the USAR's commercial manufacturing facility once commissioned in 2026. This capability now allows the Company to begin prototyping magnets and move through the qualification processes of potential customers, like Moog, as it seeks to scale up to its initial capacity next year.
"We continue our mission to bring the rare earth supply chain back to the broader technology market here in the U.S.," said Joshua Ballard, CEO of USA Rare Earth. "We are excited to support Moog in bringing their magnets back home to America, a leader in so many critical industries in need of neo magnetic applications. We look forward to building a lasting partnership for many years to come."
As part of the agreement, USA Rare Earth will design and test permanent Neodymium magnets for use in Moog's CoreMotion&#x2122; technology, which is driving energy efficiency in data centers deployed globally.

USAR

USA Rare Earth Partners With Moog to Bring Magnet Production Back to America for Global Data Centers

- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161-
-This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160-
NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits,&nbsp;today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device following the recent authorization by Anthem MultiPlan.
Depending on the individual's deductible and out-of-pocket costs, these claims may not result in an immediate PoNS Device sale.

HSDT

Helius Medical Technologies Announces Additional Authorized Claim For Payment For PoNS Device From CignaHealth

—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile—
—Patients report improved quality of life and daily functioning with ORLADEYO—

BCRX

BioCryst Reports Sustained Benefits Of Berotralstat in Children, Adolescents, And Adults With Hereditary Angioedema

Kirkland&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) will release its first-quarter financial results before the opening <a href="https://www.benzinga.com/quote/KIRK/earnings">bell on Tuesday, June 17</a>.
Analysts expect the Brentwood, Tennessee-based company to report quarterly loss at 47 cents per share, versus a year-ago loss of 65 cents per share. Kirkland&#8217;s projects quarterly revenue of $85.56 million, compared to $91.75 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 1, Kirkland's reported disappointing fourth-quarter 2024 results and warned of substantial doubt over its ability to continue as a going concern.
Kirkland&#8217;s shares fell 4.8% to close at $1.19 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/KIRK/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Benchmark analyst John Lawrence reiterated a Buy rating with a price target of $7 on Oct. 23, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Craig-Hallum analyst Jeremy Hamblin maintained a Hold rating and lowered the price target from $2.5 to $2 on Sept. 6, 2024. This analyst has an accuracy rate of 68%.</li>
</ul>
Considering buying KIRK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/KIRK/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-1024x589.png" alt="" class="wp-image-950578" style="width:704px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

Analyst Ratings

Trading Ideas

KIRK

Kirkland's Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company) presented data in a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, held June 11-14, 2025, in Barcelona, Spain. A copy of the Company's poster, titled "Advancing Fibromyalgia Treatment: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Targets Non-restorative Sleep and Provides Sustained Pain Reduction" is available under the <a href="https://www.globenewswire.com/Tracker?data=MBp6l1yE0UYuANFRaHcakT0YpPLwFdMkVv-sG5Z_BvnjCtvkoXNw7HPbhK1-zdW4JM1EJ2PYcf93TvQj_jWARwKm4AcWfMIGm6k0D9E8TBDogMAvA-Ed6lx7yGcevp8aCLRndB_H7jzMldmlI6vXVA==">Scientific Presentations</a> tab of the Tonix website at <a href="https://www.globenewswire.com/Tracker?data=mGj3zEWAkLkG6yt-vdOMKrNKcn4d98neV0wPM7Qwclwxuv_s5u9qn_RLBKTfU7dN12xCDJuWSLwAyNgezDAcmKLcaKhduNktLFfrz5YzCqE=">www.tonixpharma.com</a>. TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is a non-opioid analgesic designed for daily bedtime dosing with an FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025.

TNXP

Tonix Showcases New Fibromyalgia Drug That Targets Sleep and Pain Without Opioids

GTF maintenance agreement supports airline's long-term fleet plans
PARIS, June 16, 2025 /PRNewswire/ -- Pratt &amp; Whitney, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, and Cebu Pacific (CEB) have signed a long-term EngineWise&#x2122; comprehensive maintenance services agreement for the airline's GTF engine fleet. This agreement aligns Cebu Pacific's maintenance costs to the utilization of the airline's engines.
Currently, Cebu Pacific operates 56 Pratt &amp; Whitney powered aircraft. Prior to GTF engines, Pratt &amp; Whitney supplied JT8D engines for the airline's DC-9 aircraft fleet. Pratt &amp; Whitney and Cebu Pacific's relationship extends back to the 1990s.

RTX's Pratt & Whitney And Cebu Pacific Signs Long-Term EngineWise Comprehensive Maintenance Services Agreement For Airline's GTF Engine Fleet

Biotech

Health Care

General

OCGN

The FDA Clears Ocugen's Investigational New Drug Amendment To Initiate A Phase 2/3 Pivotal Confirmatory Trial Of OCU410ST, A Modifier Gene Therapy Candidate For All Stargardt Disease (ABCA-associated Retinopathies)

Pulmovant, a clinical-stage biotechnology company dedicated to developing innovative therapies to transform the treatment paradigm for adults suffering from pulmonary diseases and a <a href="https://www.globenewswire.com/Tracker?data=DpTIhaLdQLBte6PaVAS9H8dtbui0nzNvQvcgSeW3t9MPo7q9aXjeqGhMPmyY7008U_mXZZd2TzkLujYw8zh01w==">Roivant</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) company, today announced the publication of Phase 1 pharmacokinetics (PK) in healthy male volunteers following the administration of mosliciguat, a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, designed to provide a treatment option for patients with pulmonary hypertension (PH). The peer-reviewed manuscript titled, "Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized Phase I Studies in Healthy Men," was published in the scientific journal Clinical Pharmacokinetics. These data suggest inhaled mosliciguat has a longer half-life compared to oral and IV administration, supporting further evaluation of once-daily dosing and the potential to have limited systemic side effects when administered to patients.

ROIV

Pulmovant Unveils Phase 1 Results for Inhaled Drug Aiming to Treat Pulmonary Hypertension

TJ150 turbojet engines will power the multi-use Black Arrow missile&nbsp;
PARIS, June 16, 2025 /PRNewswire/ -- Pratt &amp; Whitney, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, has secured a contract from Dynetics, a Leidos company, to supply TJ150 engines to be integrated with their Small Cruise Missile, known as Black Arrow.
Although preliminary integration studies with Pratt &amp; Whitney commenced in 2023, work under this current contract began in April 2025 and will run through the first quarter of 2026. There is an option to provide follow-on quantities of engines. The TJ150 is in production today, and Pratt &amp; Whitney is continuing to improve upon the engine with a focus on affordability.

RTX's Pratt & Whitney Secures Contract From Dynetics To Supply TJ150 Engines To Be Integrated With Small Cruise Missile, Known As Black Arrow

OCUL

Ocular Therapeutix To Highlight Advancements In Sustained-Release Axitinib Hydrogel For Retinal Disease At CTS 2025

VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) ("VivoPower") announced today that it has engaged advisors to fast-track execution in relation to its previously announced plan to directly spin off Caret LLC ("Caret Digital") through an IPO on NASDAQ.
&nbsp;
Caret Digital's strategy will be focused on digital asset mining, with an emphasis on mining DOGE as previously announced. With the first six-month phase of mining DOGE nearing successful completion, VivoPower is confident of the scalability of the business. Leveraging DOGE mining economics, Caret Digital will convert mined DOGE into either XRP or BTC, securing both at an effective discount (based on current DOGE mining economics), which will then allow it to execute on strategies to optimise yield and returns.
The implied market capitalisation for the spin-off is US$308 million (subject to change based on market conditions and other factors). Additionally, Caret Digital intends to raise up to US$50 million from strategic investors as part of the transaction to support growth plans and it has been engaged in negotiations with counterparties in the Middle East and Asia. Since the election of US President Donald Trump and the recent investment of the Trump brothers in digital asset mining, there has been a significant increase in interest in digital asset mining activities outside of the United States, including in countries where such activity has previously been prohibited. In addition, renewable power sources at sub 3c/watt have been identified.

VVPR

VivoPower Fast-Tracks $308M Spin-Off of Crypto Unit Caret Digital Amid Global Mining Boom

<ul>
<li>Real-world data highlight significant challenges with LTP adherence, and ongoing reliance on on-demand medications.</li>
<li>In KONFIDENT-S, oral sebetralstat delivered rapid, consistent relief for breakthrough attacks, regardless of long-term prophylaxis mechanism of action</li>
</ul>

KALV

KalVista Pharmaceuticals Announced The Presentation Of New Data At The European Academy Of Allergy And Clinical Immunology Congress 2025

American Express Unveils Largest-Ever Platinum Card Refresh With Expanded Travel, Dining, And Business Perks

Approval advances transaction that will create America's leading reliable and clean energy provider, with coast-to-coast presence
Constellation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) today announced it has received regulatory approval from the New York State Public Service Commission (PSC) for its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.constellationenergy.com%2Fnewsroom%2F2025%2Fconstellation-to-acquire-calpine-creates-americas-leading-producer-of-clean-and-reliable-energy-to-meet-growing-demand-for-customers-and-communities.html&amp;esheet=54273602&amp;newsitemid=20250612288071&amp;lan=en-US&amp;anchor=previously+announced&amp;index=1&amp;md5=fa14a2fe8096a883d1ad46429eaf16b5">previously announced</a> acquisition of Calpine Corporation.
The approval represents the most recent key step forward in Constellation's plans to combine the nation's largest zero-emissions nuclear fleet with Calpine's premier portfolio of low-emission natural gas and geothermal assets. The deal will establish a coast-to-coast platform capable of supporting growing demand for around-the-clock, sustainable power.

Constellation Receives Regulatory Approval From New York State PSC For Its Previously Announced Acquisition Of Calpine Corp.

<ul>
<li>iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody</li>
<li>New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition</li>
<li>Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%&#x2A;, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23rd</li>
</ul>

IBIO

iBio Initiates Non-human Primate Study For Its Activin E Engineered Antibody Candidate, Now Named IBIO-610. This Preclinical Study Will Evaluate The Pharmacokinetics And Early Signs Of Efficacy Of IBIO-610 In Obese And Elderly NHPs, Including Its Impact On Fat And Body Composition

NXTC

NextCure Announced Strategic Partnership With Simcere Zaiming To Develop SIM0505, a CDH6-Targeting Antibody-Drug Conjugate for Solid Tumors

<ul>
<li>New Toyota&nbsp;Prius Plug-in&nbsp;Hybrid Nightshade Edition Available in 2026</li>
<li>Available in&nbsp;Karashi, Wind Chill Pearl, and Midnight Black Metallic</li>
<li>Up to 44-Miles of Manufacturer-Estimated All Electric Driving Range Rating&nbsp;</li>
<li>Up to a Manufacturer-Estimated 52 Combined MPG Rating in Hybrid Mode&nbsp;</li>
<li>Standard Toyota Audio Multimedia and Toyota Safety Sense 3.0</li>
</ul>
PLANO, Texas, June 16, 2025 /PRNewswire/ -- For 2026, Toyota is introducing the Prius Plug-in&nbsp;Hybrid Nightshade Edition – a bold new chapter in the Prius lineup that fuses sleek sophistication with an unmistakable edge. Built off the XSE grade, the Nightshade Edition elevates the iconic design with an array of captivating black accents that enhance the already stunning profile. From the sleek black badging and door sills to the stylish door handles and bumper trim, every detail has been meticulously crafted to create a cohesive and aggressive look.
The 2026 Prius Plug-in Hybrid is expected to arrive at Toyota dealerships this summer. The Manufacturer's Suggested Retail Price, excluding Dealer Processing and Handling, will start at $33,775 for the SE grade.&nbsp;
 &nbsp;

Comments

My City Builders

Interés en corto

My City Builders (OTC:MYCB) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL